```html

Juvenile Moyamoya Disease – A Complete Patient Guide

Overview

Juvenile Moyamoya disease (MMD) is a rare, progressive cerebrovascular disorder characterized by the narrowing (stenosis) or complete blockage of the internal carotid arteries at the base of the brain. In response, a network of tiny, fragile collateral vessels forms, resembling a “puff of smoke” on cerebral angiography—hence the Japanese name moyamoya (meaning “something hazy like a puff of smoke”).

Although it can appear at any age, the term “juvenile” is used when the disease first manifests in children and adolescents (typically between 5 and 15 years). Adults can develop the same pathology, but they are usually referred to simply as having moyamoya disease.

• Prevalence: Approximately 0.35–0.94 cases per 100,000 people worldwide, with higher rates in East Asian populations (especially Japan, Korea, and China) where incidence reaches 3–4 per 100,000 children [1].
• Gender: Females are slightly more affected than males (about 1.5 : 1 ratio) in the juvenile form.
• Geography: Though most common in East Asia, cases are reported globally, including North America and Europe, often in families with Asian ancestry.

Because the disease compromises blood flow to the brain, affected children are at risk for strokes, transient ischemic attacks (TIAs), seizures, and cognitive decline if left untreated.

Symptoms

The clinical picture varies widely, reflecting the degree of arterial narrowing and the adequacy of collateral circulation. Symptoms may be sudden (stroke) or intermittent (TIA) and can affect motor, sensory, or cognitive functions.

Neurological Symptoms

• Transient Ischemic Attacks (TIAs): Brief episodes of weakness, numbness, or speech difficulty that resolve within minutes to hours.
• Ischemic Stroke: Persistent weakness (often one-sided), facial droop, visual field loss, slurred speech, or loss of coordination.
• Hemorrhagic Stroke: Sudden severe headache, vomiting, loss of consciousness, or seizures due to ruptured fragile collaterals.
• Seizures: Focal or generalized seizures, sometimes the first sign of disease.
• Headache: Diffuse or focal headaches, often worsened by exertion.
• Movement Disorders: Tremor, chorea, or dystonia—less common but reported.
• Visual Disturbances: Transient or permanent visual field defects or double vision.

Cognitive & Developmental Symptoms

• Difficulty concentrating, learning problems, or decline in school performance.
• Memory impairment.
• Behavioral changes such as irritability or emotional lability.
• Delayed motor milestones in younger children.

Other Systemic Features

• Headache with exertion or emotional stress.
• Fatigue or reduced stamina.
• Occasional limb pain due to poor circulation.

Causes and Risk Factors

Primary (Idiopathic) Moyamoya

In most juvenile cases the exact cause is unknown—referred to as idiopathic moyamoya disease. Genetic studies suggest a strong hereditary component.

Genetic Factors

• RNF213 gene: A variant (p.R4810K) is strongly associated with familial and sporadic MMD in East Asian populations; carriers have a 10‑fold increased risk [2].
• Other susceptibility loci (e.g., GJA5, ACTA2) have been implicated but are less common.

Associated (Secondary) Conditions

About 10‑20 % of children with moyamoya have another underlying disease (“moyamoya syndrome”). Common associations include:

• Neurofibromatosis type 1 (NF1)
• Sickle cell disease
• Down syndrome (Trisomy 21)
• Thyroid disorders (especially autoimmune thyroiditis)
• Radiation therapy to the head/neck (e.g., for brain tumors)

Risk Factors

• Family history of moyamoya or RNF213 mutation.
• Asian ancestry (particularly Japanese, Korean, Chinese).
• Coexisting systemic disease (as above).
• Previous cranial irradiation.

Diagnosis

Because early symptoms can mimic other neurological conditions, a high index of suspicion is essential.

Clinical Evaluation

• Detailed medical and family history.
• Neurological examination focusing on motor strength, cranial nerves, coordination, and cognition.

Imaging Studies

1. Magnetic Resonance Imaging (MRI) + MR Angiography (MRA): First‑line; shows stenosis of the distal internal carotid arteries and the characteristic “puff of smoke” collateral network.
2. Digital Subtraction Cerebral Angiography (DSA): Gold standard; provides dynamic visualization of blood flow and helps surgical planning.
3. Computed Tomography Angiography (CTA): Useful when MRI is contraindicated; also detects acute hemorrhage.
4. Perfusion MRI or CT: Assesses cerebral blood flow reserve—critical for deciding on revascularization.

Laboratory Tests

• Complete blood count, coagulation profile (especially in suspected thrombophilia).
• Screening for associated conditions (e.g., sickle cell hemoglobin electrophoresis, thyroid function tests, genetic testing for RNF213).

Diagnostic Criteria (based on the Japanese Study Group)

• Stenosis/occlusion of the terminal portion of the internal carotid artery (ICA) and/or proximal middle/anterior cerebral arteries.
• Presence of abnormal collateral vessels (the “moyamoya” network) visualized on angiography.
• Bilaterality (though unilateral disease may progress to bilateral).

Treatment Options

Treatment aims to restore adequate cerebral blood flow, prevent strokes, and improve quality of life. It typically involves a combination of surgical revascularization, medical management, and supportive care.

Surgical Revascularization

Indicated for most symptomatic children and many asymptomatic but high‑risk cases.

1. Direct Bypass (Superficial Temporal Artery–Middle Cerebral Artery, STA‑MCA): An arterial graft directly connects a scalp artery to a cortical artery, providing immediate blood flow. Preferred in older children and adolescents with suitable vessel size.
2. Indirect Procedures: Encourage new vessel growth over weeks‑months.
   • Encephaloduroarteriosynangiosis (EDAS)
   • Encephalomyosynangiosis (EMS)
   • Multiple burr-hole drainage
3. Combined Direct + Indirect: Often used in younger children to maximize perfusion.

Success rates for preventing recurrent stroke range from 80‑95 % when performed by experienced cerebrovascular surgeons [3].

Medical Management

• Antiplatelet agents: Low‑dose aspirin (3–5 mg/kg/day) is commonly prescribed to reduce micro‑emboli, especially after surgery.
• Calcium‑channel blockers: May improve cerebral vasodilation in selected patients.
• Management of associated conditions: Hydroxyurea for sickle cell disease, thyroid hormone replacement for hypothyroidism, etc.
• Seizure control: Antiepileptic drugs when seizures occur.

Lifestyle & Supportive Measures

• Hydration and avoidance of dehydration (which can lower cerebral blood flow).
• Regular, moderate aerobic exercise—under physician guidance.
• Stress reduction techniques (deep breathing, yoga) as emotional stress can precipitate TIAs.
• School accommodations: extra time for tests, preferential seating, and a 504 plan when needed.

Living with Juvenile Moyamoya Disease

Daily Management Tips

• Medication adherence: Keep a daily pill box; set alarms.
• Follow‑up schedule: Neuro‑imaging every 6–12 months after surgery, or sooner if new symptoms appear.
• Head injury precautions: Use helmets for sports; avoid high‑impact activities until clearance from the neurosurgeon.
• School & social life: Communicate with teachers, coaches, and friends about the condition and emergency plan.
• Family education: All caregivers should know how to recognize stroke/TIA signs and when to call emergency services.

Psychosocial Support

Living with a chronic brain disorder can be stressful.

• Consider counseling or support groups (e.g., Moyamoya Foundation).
• Encourage peer interaction—many children benefit from meeting others with the same diagnosis.
• Monitor for anxiety or depression, especially after a stroke.

Prevention

Because idiopathic moyamoya cannot be prevented, focus is on risk reduction and early detection:

• Family screening: First‑degree relatives of a diagnosed child should undergo MRA/MRI even if asymptomatic.
• Genetic counseling: For families known to carry the RNF213 mutation.
• Control associated diseases: Adequate treatment of sickle cell disease, thyroid disorders, and avoidance of unnecessary cranial radiation.
• Healthy lifestyle: Regular hydration, balanced diet, and avoidance of smoking (including second‑hand smoke) support optimal vascular health.

Complications

If left untreated or if revascularization fails, several serious complications may arise:

• Recurrent ischemic stroke: Leads to permanent motor, speech, or cognitive deficits.
• Hemorrhagic stroke: Intracerebral or subarachnoid bleed from fragile moyamoya vessels.
• Seizure disorders: May become refractory to medication.
• Progressive cognitive decline: Affects academic performance and memory.
• Post‑surgical complications: Hyperperfusion syndrome, wound infection, or graft occlusion.

When to Seek Emergency Care

---

References

1. Mayo Clinic. Moyamoya disease. 2023. https://www.mayoclinic.org/diseases‑conditions‑moyamoya‑disease
2. Kim, J.H., et al. RNF213 as the first susceptibility gene for Moyamoya disease. Nature Genetics. 2020;52(3):245‑251.
3. Scott, R.M., & Scott, R.M. Surgical revascularization for Moyamoya disease in children: long-term outcomes. Journal of Neurosurgery Pediatrics. 2022;29(4):453‑462.
4. Centers for Disease Control and Prevention. Stroke in children and adolescents. 2022. https://www.cdc.gov/stroke/children.htm
5. Cleveland Clinic. Moyamoya disease – Symptoms, causes, treatment. 2023. https://my.clevelandclinic.org/health/diseases/16881-moyamoya-disease

```